Results of combined nivolumab and ipilimumab therapy in patients with cancer
M. A. Lyadova,
V. K. Lyadov,
O. A. Pardabekova,
I. A. Pokataev,
M. E. Ivannikov,
Ya. V. Koroleva,
E. S. Chernysheva,
K. V. Lyadov https://doi.org/10.21518/2079-701X-2021-20-18-23
Abstract
Introduction. The discovery of immune checkpoints and immune checkpoint inhibitors (ICI) became a breakthrough in medical oncology. Currently a search for most effective and safe schemes of ICI therapy for different cancers is ongoing.
Aim. To evaluate the efficacy and tolerability of a combination of nivolumab and ipilimumab in cancer patients in real-life clinical practice.
Materials and methods. The study included 30 patients: 13 patients with melanoma, 10 patients with renal cell carcinoma (RCC) and 7 patients with colorectal cancer (CRC). All patients underwent 4 courses of combined immune therapy (melanoma - nivolumab 1 mg/kg + ipilimumab 3 mg/kg; RCC, CRC – nivolumab 3 mg/kg + ipilimumab 1 mg/kg once per 21 days). Nivolumab monotherapy was continued after the achievement of disease control. Objective tumor response was registered in cases of partial or complete tumor regression. Treatment response was determined using iRECIST criteria.
Results. Treatment effect assessment was performed in 91 patients. Complete response (CR) was registered in 1 (5%) patient, partial response (PR) – in 3 (16%) patients, disease stabilization – in 8 (42%) patients, unconfirmed progression – in 7 (37%) patients. No cases of disease progression were registered. Thus, objective response rate was 21%; disease control was achieved in 63% of patients. The most significant immune-mediated adverse effects (imAEs) were gastric toxicity (20%), 1–2 grade fatigue (13%) and 2–3 grade hepatotoxicity (10%).
Conclusions. Combined nivolumab and ipilimumab therapy in patients with melanoma, CRC and RCC is associated with a high rate of disease control with acceptable toxicity profile.
About the Authors
M. A. Lyadova
City Clinical Oncological Hospital No. 1
Russian Federation
Russian Federation
Cand. Sci. (Med.), Head of the Chemotherapy Department,
26, Bldg. 2, Durov St., Moscow, 129090
V. K. Lyadov
Russian Medical Academy of Continuous Professional Education;
City Clinical Oncological Hospital No. 1
Russian Federation
Russian Federation
Head of the Department of Oncology No. 4, 26, Bldg. 2, Durov St., Moscow, 129090;
Dr. Sci. (Med.), Associate Professor, Department of Oncology, 2/1, Bldg. 1, Barrikadnaya St., Moscow, 125993
O. A. Pardabekova
City Clinical Oncological Hospital No. 1;
Moscow Center for Rehabilitation
Russian Federation
Russian Federation
Oncologist, Chemotherapy Department, 26, Bldg. 2, Durov St., Moscow, 129090;
Oncology Department of Anticancer Drug Therapy, 16, Bldg. 1, Orshanskaya St., Moscow, 121552
I. A. Pokataev
City Clinical Oncological Hospital No. 1
Russian Federation
Russian Federation
Dr. Sci. (Med.), Head of the Chemotherapeutic Treatment Service,
26, Bldg. 2, Durov St., Moscow, 129090
M. E. Ivannikov
Moscow Regional Oncological Dispensary
Russian Federation
Russian Federation
Oncologist, Consultative and Diagnostic Department,
6, Karbyshev St., Moscow region, Balashikha, 143900
Ya. V. Koroleva
Moscow Center for Rehabilitation
Russian Federation
Russian Federation
Senior Administrator of the Oncology Department of Anticancer Drug Therapy,
16, Bldg. 1, Orshanskaya St., Moscow, 121552
E. S. Chernysheva
Moscow Center for Rehabilitation
Russian Federation
Russian Federation
Cand. Sci. (Med.), Deputy Chief Physician for Clinical Work,
16, Bldg. 1, Orshanskaya St., Moscow, 121552
K. V. Lyadov
Moscow Center for Rehabilitation
Russian Federation
Russian Federation
Acad. RAS, Dr. Sci. (Med.), Professor, Honored Doctor of the Russian Federation, Chief Physician,
16, Bldg. 1, Orshanskaya St., Moscow, 121552
References
1. Tan S., Li D., Zhu X. Cancer Immunotherapy: Pros, Cons and Beyond. Biomed Pharmacother. 2020;124:109821. https://doi.org/10.1016/j.biopha. 2020.109821.
2. Hegde P.S., Chen D.S. Top 10 Challenges in Cancer Immunotherapy. Immunity. 2020;52(1):17–35. https://doi.org/10.1016/j.immuni.2019.12.011.
3. Kruger S., Ilmer M., Kobold S., Cadilha B.L., Endres S., Ormanns S. et al. Advances in Cancer Immunotherapy 2019 – Latest Trends. J Exp Clin Cancer Res. 2019;38(1):268. https://doi.org/10.1186/s13046-019-1266-0.
4. Onitilo A.A., Wittig J.A. Principles of Immunotherapy in Melanoma. Surg Clin North Am. 2020;100(1):161–173. https://doi.org/10.1016/j.suc.2019.09.009.
5. Kottschade L.A. The Future of Immunotherapy in the Treatment of Cancer. Semin Oncol Nurs. 2019;35(5):150934. https://doi.org/10.1016/j.soncn.2019.08.013.
6. Abbott M., Ustoyev Y. Cancer and the Immune System: The History and Background of Immunotherapy. Semin Oncol Nurs. 2019;35(5):150923. https://doi.org/10.1016/j.soncn.2019.08.002.
7. Kennedy L.B., Salama A.K.S. A Review of Cancer Immunotherapy Toxicity. CA Cancer J Clin. 2020;70(2):86–104. https://doi.org/10.3322/caac.21596.
8. Reutova E.V., Laktionov K.P., Breder V.V., Sarantseva K.A., Okruzhnova M.A., Peregudova M.V. Immune-Mediated Adverse Events Associated with Immune Checkpoint Inhibitors Therapy. Zlokachestvennyye opukholi = Malignant Tumours. 2016;(4):68–76. (In Russ.) https://doi.org/10.18027/2224-5057-2016-4-68-76.
9. Lyadova M.A., Pardabekova O.A., Shakirov R.R., Lyadov V.K., Fedyanin M.Yu. Nivolumab in real-life clinical practice. Issledovaniya i praktika v meditsine = Research and Practical Medicine Journal. 2019;6(4):84–91. (In Russ.) https://doi.org/10.17709/2409-2231-2019-6-4-8.
10. Zhou S., Khanal S., Zhang H. Risk of Immune-Related Adverse Events Associated with Ipilimumab-Plus-Nivolumab and Nivolumab Therapy in Cancer Patients. Ther Clin Risk Manag. 2019;15:211–221. https://doi.org/10.2147/TCRM.S193338.
11. Brahmer J.R., Drake C.G., Wollner I., Powderly J.D., Picus J., Sharfman W.H. et al. Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates. J Clin Oncol. 2010;28(19):3167–3175. https://doi.org/10.1200/JCO.2009.26.7609.
12. Topalian S.L., Drake C.G., Pardoll D.M. Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy. Cancer Cell. 2015;27(4):450–461. https://doi.org/10.1016/j.ccell.2015.03.001.
13. Bray F., Ferlay J., Soerjomataram .I, Siegel R.L., Torre L.A., Jemal A. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.
14. Cronin K.A., Lake A.J., Scott S., Sherman R.L., Noone A.M., Howlader N. et al. Annual Report to the Nation on the Status of Cancer, part I: National Cancer Statistics. Cancer. 2018;124(13):2785–2800. https://doi.org/10.1002/cncr.31551.
15. Van der Geest L.G., Lam-Boer J., Koopman M., Verhoef C., Elferink M.A., de Wilt J.H. Nationwide Trends in Incidence, Treatment and Survival of Colorectal Cancer Patients with Synchronous Metastases. Clin Exp Metastasis. 2015;32(5):457–465. https://doi.org/10.1007/s10585-015-9719-0.
16. Mattiuzzi C., Sanchis-Gomar F., Lippi G. Concise Update on Colorectal Cancer Epidemiology. Ann Transl Med. 2019;7(21):609. https://doi.org/10.21037/atm.2019.07.91.
17. Overman M.J., Lonardi S., Wong K.Y.M., Lenz H.J., Gelsomino F., Aglietta M. et al. Durable Clinical Benefit with Nivolumab plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin Oncol. 2018;36(8):773–779. https://doi.org/10.1200/JCO.2017.76.9901.
18. Eggermont A.M., Spatz A., Robert C. Cutaneous Melanoma. Lancet. 2014;383(9919):816–827. https://doi.org/10.1016/S0140-6736(13)60802-8.
19. Gwadry-Sridhar F., Nikan S., Hamou A., Seung S.J., Petrella T., Joshua A.M. et al. Resource Utilization and Costs of Managing Patients with Advanced Melanoma: A Canadian Population-Based Study. Curr Oncol. 2017;24(3):168–75. https://https://doi.org/.org/10.3747/co.24.3432.
20. Szczepaniak Sloane R.A., Gopalakrishnan V., Reddy S.M., Zhang X., Reuben A., Wargo J.A. Interaction of Molecular Alterations with Immune Response in Melanoma. Cancer. 2017;123(S11):2130–2142. https://https://doi.org/.org/10.1002/cncr.30681.
21. Twitty C.G., Huppert L.A., Daud A.I. Prognostic Biomarkers for Melanoma Immunotherapy. Curr Oncol Rep. 2020;22(3):25. https://doi.org/10.1007/s11912-020-0886-z.
22. Benlalam H., Labarrière N., Linard B., Derré L., Diez E., Pandolfino M.C. et al. Comprehensive Analysis of the Frequency of Recognition of Melanoma-Associated Antigen (MAA) by CD8 Melanoma Infiltrating Lymphocytes (TIL): Implications for Immunotherapy. Eur J Immunol. 2001;31(7):2007–2015. https://doi.org/10.1002/1521-4141(200107) 31:73.0.co;2-s.
23. Rohaan M.W., van den Berg J.H., Kvistborg P., Haanen J.B.A.G. Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Melanoma: A Viable Treatment Option. J Immunother Cancer. 2018;6(1):102. https://doi.org/10.1186/s40425-018-0391-14.
24. Motofei I.G. Melanoma and Autoimmunity: Spontaneous Regressions as a Possible Model for New Therapeutic Approaches. Melanoma Res. 2019;29(3):231–236. https://doi.org/10.1097/CMR.0000000000000573.
25. Hua C., Boussemart L., Mateus C., Routier E., Boutros C., Cazenave H. et al. Association of Vitiligo with Tumor Response in Patients with Metastatic Melanoma Treated with Pembrolizumab. JAMA Dermatol. 2016;152(1): 45–51. https://doi.org/10.1001/jamadermatol.2015.2707.
26. Larkin J., Chiarion-Sileni V., Gonzalez R., Grob J.J., Rutkowski P., Lao C.D. et al. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019;381(16):1535–1546. https://doi.org/10.1056/NEJMoa1910836.
27. Kulik L., El-Serag H.B. Epidemiology and Management of Hepatocellular Carcinoma. Gastroen Terology. 2019;156(2):477.e1–491.e1. https://doi.org/10.1053/j.gastro.2018.08.065.
28. Motzer R.J., Tannir N.M., McDermott D.F., Arén Frontera O., Melichar B., Choueiri T.K. et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018;378(14):1277–1290. https://doi.org/10.1056/NEJMoa1712126.
29. Jonasch E. Updates to the Management of Kidney Cancer. J Natl Compr Canc Netw. 2018;16(5S):639–641. https://doi.org/10.6004/jnccn.2018.0039.
30. Brown L.C., Desai K., Zhang T., Ornstein M.C. The Immunotherapy Landscape in Renal Cell Carcinoma. BioDrugs. 2020;34(6):733–748. https://doi.org/10.1007/s40259-020-00449-4.
Review
For citations:
Lyadova MA, Lyadov VK, Pardabekova OA, Pokataev IA, Ivannikov ME, Koroleva YV, Chernysheva ES, Lyadov KV. Results of combined nivolumab and ipilimumab therapy in patients with cancer. Meditsinskiy sovet = Medical Council. 2021;(20):18-23. (In Russ.) https://doi.org/10.21518/2079-701X-2021-20-18-23
Views:
470
Email this article 